Analytica markAnalytica
← Analytica Weekly

Pre-AGM Season Briefing: Navigating the March–April 2026 Korean Proxy Calendar

The Calendar: What to Expect and When

As of February 24, AGM filings are beginning to accumulate on the Korea Exchange, and the shape of the March–April 2026 proxy calendar is already visible. Based on preliminary filings received through this week, Analytica expects approximately 450 KOSPI companies to hold AGMs in March and April — a figure consistent with historical patterns, though the concentration in the April 1–18 window is expected to be higher than in prior years. Roughly 60% of KOSPI 200 companies currently have AGMs scheduled for that window, creating the same logistical compression that frustrated institutional investors in the 2025 season. A cluster of ten high-market-cap companies — including names in semiconductors, automotive, and steel — have filed meeting notices for April 7–9 alone. Investors without an organized workflow for simultaneous-meeting weeks should address that now, before the calendar locks in entirely.

The March meetings — earlier movers, typically in financial services, utilities, and some large-cap industrials — offer a useful rehearsal window. Governance policies, ESG documentation frameworks, and proxy advisory coverage agreements should all be confirmed before the first March votes are counted. Based on pre-filings reviewed as of this week, Analytica expects at least fifteen March meetings where contested resolutions will require substantive engagement or careful vote analysis, rather than routine processing.

Key Themes Setting the Agenda for 2026

Three overarching themes are already evident in early filings and pre-season engagement activity, and investors should expect these to dominate the advisory landscape through April. First, board composition under heightened NPS scrutiny: the National Pension Service's revised proxy voting policy, effective January 2026, establishes an explicit one-third independent director threshold with substance requirements — nominees whose independence is formal rather than functional will draw NPS opposition. At six KOSPI 100 companies where Analytica has reviewed pre-filed director slates as of this week, at least one nominee's independence is legitimately in question under the new NPS standard. Second, executive remuneration transparency: the FSS signaled in its December 2025 supervisory communication that individual pay disclosure for top executives will be a stewardship examination focus in 2026. Companies that have not updated their remuneration disclosures since the 2025 regulatory guidance face heightened investor opposition this cycle. Third, capital return credibility: the corporate value-up program launched by the FSC in mid-2025 has prompted a wave of buyback and dividend announcements, but Analytica's preliminary screening suggests that a meaningful proportion lack the multi-year frameworks that distinguish credible capital return programs from one-off gestures.

Contested Resolutions: Early Indications

Based on filings, engagement activity, and public statements through February 24, Analytica is tracking resolutions at seventeen KOSPI-listed companies that have a meaningful probability of becoming genuinely contested — meaning live opposition campaigns with organized institutional support, not merely dissenting recommendations from a single advisory firm. The most significant cluster involves director elections at chaebol affiliates where controlling family nominees face credibility challenges on independence or qualification grounds. Three companies in this group have already attracted pre-season correspondence from foreign institutional investors calling for reconsideration of the director slate — an unusual step that signals the level of organized intent entering this season.

Beyond director elections, dividend-related shareholder proposals merit particular attention. A coordinated campaign by three domestic asset managers — publicly announced in mid-February — targets seven cash-rich mid-cap industrials with proposals to increase minimum payout ratios. As of this writing, none of the targeted companies has entered into dialogue with the proposing institutions. Analytica is evaluating each situation against its capital return framework and will publish recommendations on a rolling basis from mid-March. Investors with positions in any of the seven companies should not wait for the advisory recommendation before engaging directly with investor relations; the pre-AGM window for negotiated settlements typically closes three to four weeks before meeting dates.

How to Use This Season Effectively

Foreign institutional investors often approach the Korean AGM season reactively — reviewing recommendations as they arrive and voting without the benefit of pre-season positioning. The 2026 season rewards a different approach. Given the NPS policy changes, the FSS stewardship guidance updates expected in late February, and the volume of contested situations already visible, investors who have not reviewed their proxy voting policies for Korea-specific compliance should do so before March meetings begin. Key questions to address now: Does your current policy explicitly address the NPS one-third independent director standard? Are your documentation procedures sufficient to satisfy the FSS stewardship examination criteria anticipated for Q3 2026? Have you confirmed your proxy advisory coverage for the April peak?

  • ~450 KOSPI AGMs expected in March–April; roughly 60% of KOSPI 200 concentrated in April 1–18
  • At least 15 March meetings expected to involve contested or complex resolutions
  • 17 companies tracked by Analytica with meaningful contested-resolution probability as of Feb 24
  • NPS one-third independent director policy effective January 2026; already affecting slate evaluations
  • Coordinated dividend campaign targets 7 mid-cap industrials; no issuer dialogue initiated as of this week

Analytica Coverage Positioning for 2026

Analytica is entering the 2026 AGM season with expanded coverage of KOSPI 200 companies and a new rapid-response format for contested situations — clients in contested situations will receive preliminary recommendations ten business days before each meeting and a final recommendation five business days before, with a summary of any material developments in the intervening period. For the April cluster, Analytica has structured its analytical workflow around the April 1–18 concentration window to ensure no recommendation is delayed by volume. Clients who have not yet confirmed their 2026 coverage roster should do so this week to ensure onboarding is complete before March filings accelerate. The season does not wait.

References

  1. Korea Exchange (KRX), "Preliminary AGM Filing Registrations — February 2026," KRX Market Operations, February 2026. Available from: krx.co.kr
  2. National Pension Service (NPS), "2026 Proxy Voting Policy (Revised)," NPS Fund Management, January 2026. Available from: nps.or.kr
  3. Financial Supervisory Service (FSS), "Supervisory Communication on Stewardship and Remuneration Disclosure," FSS Regulatory Guidance, December 2025. Available from: fss.or.kr
  4. Financial Services Commission (FSC), "Corporate Value-Up Program: Progress Report and 2026 Priorities," FSC Policy Announcements, February 2026. Available from: fsc.go.kr
  5. Choi Y. and Baek J., "Institutional Investor Coordination in Korean Proxy Campaigns: Evidence from 2023–2025," Asia-Pacific Journal of Financial Studies, Vol. 55, No. 1, January 2026.